A Phase II Single Arm Trial of Palonosetron (PALO) for the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma (MG) Patients Receiving Irinotecan in Combination With Bevacizumab

Trial Profile

A Phase II Single Arm Trial of Palonosetron (PALO) for the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma (MG) Patients Receiving Irinotecan in Combination With Bevacizumab

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 May 2014

At a glance

  • Drugs Palonosetron (Primary) ; Dexamethasone
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Mar 2014 Planned number of patients changed from 80 to 63 as reported by ClinicalTrials.gov.
    • 31 Mar 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 23 Apr 2013 Planned end date changed from 1 Jul 2014 to 1 Jan 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top